Dallah Healthcare Co. · TADAWUL:4004
Dallah Healthcare — FY2025 Earnings Presentation
27 slides from Dallah Healthcare's earnings presentation, 2025
Slide 1: Dallah Healthcare Co. FY 2025
Dallah Healthcare Co. FY 2025
Slide 2: Today's Speakers and Agenda
Today’s Speakers and Agenda 1. About us 2. Business Review 3. Financial Review Abdulaziz Alwohaibi Amine A.Hariz Omar Aljabari Saud Alraqraq Chief Operating Officer Chief Financial Officer Chief Commercial Officer Chief Corporate Affairs Officer
Slide 3: DHC's mission and vision guided by core values
DHC’s mission and vision … … guided by core values Mission Values To deliver excellent healthcare services Care and respect for our patients, which are consistent with our values and their needs and our society with the expectation of our patients, society, and partners Commitment to professional et
Slide 4: Dallah Healthcare Company offers an attractive investment opportunity
DHC has long been established in KSA and has shown year-on-year growth DHC has a strong product portfolio, consistently growing to address the evolving needs of patients Dallah Healthcare Company offers an DHC has numerous certifications positioning it at the forefront in terms of service excellence
Slide 5: History: DHC has a long legacy in the healthcare space in KSA
Dallah Hospital- Al Nakheel 1987 Dallah Pharma 2002 Dallah Ob-gyne 2007 2012 DHC listing Dallah Pediatrics 2013 Jordanian Pharmaceuticals Co. Afyaa Al Nakheel 2014 and DMRF North clinics 2015 quite rapidly both organically and inorganically Dallah Hospital- Namar 2018 Dallah Al Nakheel Meras Arabia
Slide 6: Portfolio: DHC owns and operates five categories of companies
Dallah Health Company Portfolio Today, DHC owns and directly operates five categories of companies while also engaging in active management of portfolio investments Owned & operated by DHC Portfolio investments (ownership share, %) Hospitals Clinics Dr. MRF Hospital* (31.2%) Meras Clinics* (35.6%) H
Slide 7: DHC's longstanding presence in KSA and integrated portfolio of services
13 +2,560 Healthcare Facilities Beds DHC’s longstanding presence in KSA and integrated portfolio of services position it +21% 18% Patients Volume CAGR Net Profit as a leader in service FY21-25 CAGR FY21-25 excellence, quality, and patient safety 5 +207 Medical specialties & Cities around KSA special
Slide 8: Awards and Honours
ICHOM “Most Contributing Leading Hospital” The 1st Saudi hospital to receive the new version of ICHOM Accreditation By CHI “Ribbons 5” rating - The highest “Excellence in Patient Satisfaction” level of achievement in the Awards and Honours implementation of (PROMS).” by the Global Patient Experience
Slide 9: With +2,560 beds, DHC aims to further expand to meet future demand
Dallah Health Company Portfolio With +2,560 beds, DHC aims to further expand to meet future demand Combined current capacity at +2,560 beds across DHC's operational entities and investments Companies owned & operated by 540 300 475 274 180 4 3 DHC beds beds beds beds beds Location Cities Portfolio i
Slide 10: Future Projects
Dallah Health Company Portfolio Future Projects Dallah Alarid Hospital Wahat Al-Nakheel Real Estate Fund • Land: 45,000 sqm • DHC, Dallah Real Estate, Aljazira Capital, and Tatweer signed MoU to establish a • Built-up area: 87,300 sqm private real estate fund. • 250 Beds • An estimated value exceedi
Slide 11: DHC's presence across the Kingdom of Saudi Arabia
DHC's presence Al Khobar اخلرب across the Al Hofouf Riyadh اهلفوف Kingdom of الرياض Saudi Arabia Jeddah جدةMakkah مكة املكرمة 10
Slide 12: Array of medical services offered by DHC hospitals
Dallah Health Company Portfolio The array of medical services offered by DHC hospitals extends across various specialties, complemented by supplementary support services 207+ Medical specialties and subspecialties 4+ key Ancillary Services Medical services under the following therapy areas: Suppleme
Slide 13: Consistent patient volume growth over the past 5 years
Dallah Health Company Portfolio Over the past 5 years, DHC's hospitals have demonstrated consistent patient volume growth, with 1 million visits increase in 2025 comparing to 2024 Patient volume (in 000s) CAGR 33.5% 20.5% 3,792 2,839 2,737 2,252 1,800 2021 2022 2023 2024 2025 • MMC and KHCC were add
Slide 14: Accreditations: certifications, accreditations and awards
Dallah Health Company Accreditations When addressing service excellence and patient safety, DHC has acquired several well-regarded certifications, accreditations, and awards One of the first hospitals in Dallah Hospital laboratory Dallah Hospitals catering Saudi Arabia awarded JCI certified by the C
Slide 15: DHC's Journey to Value-Based Healthcare
DHC’ Journey to Value-Based Healthcare DHC's is dedicated to leading the way in VBHC, ultimately delivering greater value and improved health outcomes for our patients Key initiatives: Pilot Programs Strategic Collaborations Future Focus • PROM & PREM with a Major Insurer • The Center for Value in H
Slide 16: Growth Strategy & Leadership: well-defined 5-year strategy
Dallah Health Company Growth Strategy & Leadership DHC's future growth is supported by its well-defined 5-year strategy anchored around a coherent direction for the diversified portfolio Deep-dive included in the next slides Operating companies Investments Become a one-stop shop for VIP/A privately
Slide 17: Becoming a 'one-stop high-end' service provider
Dallah Health Company Growth Strategy & Leadership To become a 'one-stop high-end' service provider, DHC will selectively specialize as well as expand into clinics, telemedicine, post-acute care and homecare Value One-stop-shop high-end provider First point of contact from the cradle to the grave Pr
Slide 18: Strong financial performance between 2024 and 2025, 10% EPS growth
Dallah Health Company Financial Performance DHC has experienced a strong financial performance between year-2024 and year-2025, leading to 10% EPS growth Key consolidated financial metrics (SAR M) Year-2024 Year-2025 Revenues 3,206 26.9% 4,067 EBITDA 751 22.8% 922 EBIT 610 14.3% 697 Net Profit 485 1
Slide 19: Current yearly revenue run-rate in FY25 almost double FY21
Dallah Health Company Financial Performance Current yearly revenue run-rate in FY25 is almost double of FY21 Revenues (SAR M) CAGR 18% 26.9% 4,067 3,206 2,943 2,488 2,105 2021 2022 2023 2024 2025 18
Slide 20: Transitory pressure on gross margin due to the acquisition
Dallah Health Company Financial Performance Transitory pressure on gross margin due to the acquisition, with Dallah Al- Khobar profitability now ahead of management’s pre-transaction assessment Gross Profit (SAR M) CAGR 2000 20.3% 18% 38% 40% 1800 37% 36% 36% 36% 1600 35% 1400 1,452 30% 1200 25% 1,2
Slide 21: Operational excellence compounding growth with rising margins (EBIT)
Dallah Health Company Financial Performance DHC’s operational excellence has compounded growth in value with rise in profitability margins, unlocking substantial shareholder value 900 30% EBIT (SAR M) 800 CAGR 14.3% 20% 25% 700 697 19% 20% 600 17% 610 17% 16% 16% 500 15% 504 400 400 10% 300 334 5% 2
Slide 22: EBITDA margin highly resilient post-acquisition
Dallah Health Company Financial Performance EBITDA margin highly resilient post-acquisition EBITDA (SAR M) 30% CAGR 1100 22.8% 20% 25% 23% 23% 21% 21% 900 21% 922 20% 700 751 15% 630 500 514 10% 449 300 5% 100 0% 2021 2022 2023 2024 2025 EBITDA Margin 21
Slide 23: Earnings growth shows strong momentum since 2021
Dallah Health Company Financial Performance Earnings growth shows strong momentum since 2021 Net Profit (SAR M) 700 16% 15% CAGR 11.4% 18% 13% 14% 600 13% 13% 12% 541 12% 500 485 10% 400 385 8% 300 295 6% 275 200 4% 100 2% 0 0% 2021 2022 2023 2024 2025 EBITDA Margin 22
Slide 24: Q4-2025 highest quarter ever in terms of revenues
Dallah Health Company Financial Performance Q4-2025 highest Quarter ever in terms of revenues, with current run-rate establishing a strong base for 2026 Revenues (SAR M) 1,110 1,062 1,061 848 833 809 784 765 Q1-2024 Q2-2024 Q3-2024 Q4-2024 Q1-2025 Q2-2025 Q3-2025 Q4-2025 23
Slide 25: Decreasing leverage trend and bonus shares announced
Dallah Health Company Financial Performance DHC pursuing long-term trend of decreasing leverage and announces bonus shares, with temporary debt surges solely linked to its growth strategy Net debt-to-EBITDA and Gearing ratio 3.7x 3.3x 2.6x 2.3x 3.9x 86% 79% 76% 3,552 48% 46% 1,659 1,697 1,659 1,731
Slide 26: Healthy return on equity averaging 14% over 5 years
Dallah Health Company Financial Performance DHC achieved a healthy return on equity in the past 5 years, averaging 14%, despite the surge in the equity base Return on Equity 14.2% 14.3% 14.1% 13.9% 13.9% 2021 2022 2023 2024 2025 25
Slide 27: Thank you
Thank you